| IDH mutation in glioma: molecular mechanisms and potential therapeutic targets S Han, Y Liu, SJ Cai, M Qian, J Ding, M Larion, MR Gilbert, C Yang British journal of cancer 122 (11), 1580-1589, 2020 | 455 | 2020 |
| Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia Z Zhuang, C Yang, F Lorenzo, M Merino, T Fojo, E Kebebew, V Popovic, ... New England Journal of Medicine 367 (10), 922-930, 2012 | 412 | 2012 |
| A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma FR Lorenzo, C Yang, M Ng Tang Fui, H Vankayalapati, Z Zhuang, ... Journal of molecular medicine 91, 507-512, 2013 | 208 | 2013 |
| Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair Y Lu, J Kwintkiewicz, Y Liu, K Tech, LN Frady, YT Su, W Bautista, SI Moon, ... Cancer research 77 (7), 1709-1718, 2017 | 206 | 2017 |
| Evaluating in vitro DNA damage using comet assay Y Lu, Y Liu, C Yang JoVE (Journal of Visualized Experiments), e56450, 2017 | 191 | 2017 |
| Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction I Jochmanová, C Yang, Z Zhuang, K Pacak Journal of the National Cancer Institute 105 (17), 1270-1283, 2013 | 184 | 2013 |
| New syndrome of paraganglioma and somatostatinoma associated with polycythemia K Pacak, I Jochmanova, T Prodanov, C Yang, MJ Merino, T Fojo, ... Journal of clinical oncology 31 (13), 1690-1698, 2013 | 153 | 2013 |
| Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia C Yang, Z Zhuang, SMJ Fliedner, U Shankavaram, MG Sun, P Bullova, ... Journal of Molecular Medicine 93, 93-104, 2015 | 152 | 2015 |
| Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms EK Nduom, C Yang, MJ Merrill, Z Zhuang, RR Lonser Journal of neurosurgery 119 (2), 427-433, 2013 | 129 | 2013 |
| New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma L Dimitrov, CS Hong, C Yang, Z Zhuang, JD Heiss International journal of medical sciences 12 (3), 201, 2015 | 126 | 2015 |
| Brusatol, an NRF2 inhibitor for future cancer therapeutic SJ Cai, Y Liu, S Han, C Yang Cell & bioscience 9, 1-3, 2019 | 109 | 2019 |
| LB100, a small molecule inhibitor of PP2A with potent chemo-and radio-sensitizing potential CS Hong, W Ho, C Zhang, C Yang, JB Elder, Z Zhuang Cancer biology & therapy 16 (6), 821-833, 2015 | 109 | 2015 |
| Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism D Yu, Y Liu, Y Zhou, V Ruiz-Rodado, M Larion, G Xu, C Yang Proceedings of the National Academy of Sciences 117 (18), 9964-9972, 2020 | 103 | 2020 |
| Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas C Yang, MG Sun, J Matro, TT Huynh, S Rahimpour, JT Prchal, R Lechan, ... Blood, The Journal of the American Society of Hematology 121 (13), 2563-2566, 2013 | 101 | 2013 |
| Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury J Lu, JM Frerich, LC Turtzo, S Li, J Chiang, C Yang, X Wang, C Zhang, ... Proceedings of the National Academy of Sciences 110 (26), 10747-10752, 2013 | 100 | 2013 |
| Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease J Lu, C Yang, M Chen, DY Ye, RR Lonser, RO Brady, Z Zhuang Proceedings of the National Academy of Sciences 108 (52), 21200-21205, 2011 | 99 | 2011 |
| Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones C Yang, S Rahimpour, J Lu, K Pacak, B Ikejiri, RO Brady, Z Zhuang Proceedings of the National Academy of Sciences 110 (3), 966-971, 2013 | 94 | 2013 |
| Overexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal cancer tissue Y Lu, W Wang, J Wang, C Yang, H Mao, X Fu, Y Wu, J Cai, J Han, Z Xu, ... PloS one 8 (9), e73866, 2013 | 91 | 2013 |
| Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy H Xu, S Rahimpour, CL Nesvick, X Zhang, J Ma, M Zhang, G Zhang, ... Oncotarget 6 (14), 11882, 2015 | 87 | 2015 |
| β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas C Yang, RR Iyer, ACH Yu, RL Yong, DM Park, RJ Weil, B Ikejiri, RO Brady, ... Proceedings of the National Academy of Sciences 109 (18), 6963-6968, 2012 | 85 | 2012 |
Karel Pacak在 mail.nih.gov 的电子邮件经过验证
